Improving treatment response in aggressive endometrial cancer by inhibiting AXL
Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer
This study is looking at how well a new drug called batiraxcept works with a common chemotherapy drug, paclitaxel, to help people with aggressive types of endometrial cancer, and it aims to find out if this combination is safe and if certain markers can help predict how well patients will respond to the treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10912618 on NIH RePORTER |
What this research studies
This research investigates the potential of a drug called batiraxcept to enhance the effectiveness of standard treatments for aggressive forms of endometrial cancer, specifically uterine serous cancer and high-grade endometrioid tumors. The study aims to determine the safety and tolerability of combining batiraxcept with paclitaxel, a common chemotherapy drug, while also identifying biomarkers that may predict treatment response. By targeting the AXL pathway, which is linked to poor survival rates in these cancers, the research seeks to improve patient outcomes through a more personalized treatment approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with recurrent uterine serous cancer or grade 3 endometrioid endometrial cancer.
Not a fit: Patients with early-stage endometrial cancer or those not diagnosed with aggressive histologies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment responses and survival rates for patients with aggressive endometrial cancer.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting the AXL pathway in other cancer types, suggesting potential for success in this context.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Mutch, David G — Washington University
- Study coordinator: Mutch, David G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.